Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKinsey
Johnson and Johnson
McKesson
Express Scripts

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR PROMETRIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Prometrium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00152438 ↗ Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone Unknown status University of British Columbia Phase 2 2005-09-01 The primary purpose of this study is to determine the effects of a full dose (300 mg at hs) of oral micronized progesterone (OMP) on vasomotor symptoms [VMS] (hot flushes/night sweats), on forearm blood flow and on lipid levels and blood pressure in menopausal women without cardiovascular disease and with moderate to severe VMS. The hypotheses are that progesterone will improve hot flushes, increase endothelium-dependent forearm blood flow and will decrease blood pressure without change in lipid levels.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Albert Einstein College of Medicine Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗ Kronos Early Estrogen Prevention Study (KEEPS) Unknown status Albert Einstein College of Medicine of Yeshiva University Phase 4 2005-09-01 The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Prometrium

Condition Name

Condition Name for Prometrium
Intervention Trials
Menopause 5
Suicidal Ideation 3
Preterm Birth 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Prometrium
Intervention Trials
Amenorrhea 4
Suicidal Ideation 3
Premature Birth 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Prometrium

Trials by Country

Trials by Country for Prometrium
Location Trials
United States 110
Canada 5
Italy 1
Israel 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Prometrium
Location Trials
North Carolina 11
California 8
Connecticut 7
Pennsylvania 5
Illinois 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Prometrium

Clinical Trial Phase

Clinical Trial Phase for Prometrium
Clinical Trial Phase Trials
Phase 4 13
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Prometrium
Clinical Trial Phase Trials
Completed 17
Recruiting 7
Unknown status 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Prometrium

Sponsor Name

Sponsor Name for Prometrium
Sponsor Trials
National Institute of Mental Health (NIMH) 8
University of North Carolina, Chapel Hill 7
National Institute on Drug Abuse (NIDA) 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Prometrium
Sponsor Trials
Other 66
NIH 25
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Johnson and Johnson
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.